Unlucky women with BIA-ALCL: An update

February 17, 2019 – The unfortunate recognition of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a very rare form of a T-cell lymphoma, gains more momentum by the day. This is actually very positive a development, because it helps women who are getting breast implants for whatever reasons to better known associated health risks,

Read more ›



Caplacizumab-yhdp (Cablivi): the first therapy for the treatment of aTTP

February 07, 2019 – The American Food and Drug Administration (FDA) just approved Caplacizumab-yhdp (Cablivi), the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP),

Read more ›



Hydrochlorothiazide and non-melanoma skin cancer: How come?

February 02, 2019 –  This is potential alarming news for millions of patients worldwide suffering from high blood pressure: Health Canada has just completed a safety review of hydrochlorothiazide and has found that prolonged use of the drug could increase a person’s risk for non-melanoma skin cancer.

Read more ›



Pharmacogenomics of Anticoagulants: Newly Identified Genes and Genetic Variants

January 26, 2019 – Pharmacogenomic approaches are increasingly revealing newly identified genes and genetic variants that are at the base of remarkable inter-individual pharmacokinetic and pharmacodynamic variation of novel direct oral anticoagulants (DOAC).

Read more ›



Stuff to read: Why should our Y chromosome disappear, after all?

January 21, 2019 – Stuff to Read: As the Y chromosome is disappearing, we prepare ourselves to say goodbye to men, while asking if we could, and/or should, engineer animals to be as smart as us as humans?

As the person behind thasso.com and the writer of some of the posts to be found on thasso post,

Read more ›



Febuxostat (Uloric) and its problem with cardiovascular mortality

January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. Febuxostat (Uloric) was approved by the American Food and Drug Administration (FDA) in 2009 for the chronic management of hyperuricemia in patients with gout.

Read more ›



Combined hormonal contraception: Is there an unacceptable health risk?

January 15, 2019 – The World Health Organization (WHO) classifies combined hormonal contraception as an unacceptable health risk in the presence of a known thrombogenic mutation but advises against routine thrombophilia genetic testing before initiating combined oral contraceptives (COC’s) on the grounds of high screening costs and low prevalence.

Read more ›



Sweet taste receptor gene TAS1R2 and chocolate powder

January 13, 2019 – Are genetic variations in the sweet taste receptor gene related to chocolate powder and dietary fiber intake in obese children and adolescents? This was the question in a recent study just published in the Journal of Personalized Medicine. On one hand,

Read more ›



Migalastat (Galafold): New treatment for Fabry disease

January 12, 2018 – Fabry disease is an inherited disorder caused by mutations (alterations) in the alpha-galactosidase A (GLA) gene located on the X-chromosome. Fabry disease is rare and affects both males and females. It is estimated that classic Fabry disease (the most severe type) affects approximately one in 40,000 males.

Read more ›



Is there breast implant-associated cancer (BIA-ALCL)?

January 09, 2019 – Women should be alerted: Is there a thing like breast implant associated cancer (BIA-ALCL)? Yes, there is. Not every woman with a breast implant will get it, however. In fact, BIA-ALCL seems to be a rather rare condition; unfortunately,

Read more ›



thasso: conditions

thasso: tweets

thasso: patient voices


Powered by Treato.com

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

Top